bit X bio

Technology Advancement

Adimune

Current standards for treatment of autoimmune diseases rely largely on suppression of the immune system.  While these therapies can be effective in addressing the signs and symptoms of the disease condition, they do not address the root cause and repeated administration of the drug is required, which may lead to increased risk of developing serious infections and cancer.  Adimune is developing a technology called ADI™ (Apoptotic DNA Immunotherapy™) with a goal of mimicking physiological pathways to train the body’s immune system to become tolerant to the tissue it is attacking.  Adimune’s first product candidate, ADI-100™, is in final stages of preparation for regulatory submission to initiate first-in-human studies.  Adimune is also developing an AI platform to accelerate and optimize additional products for other autoimmune indications.

Pearsanta

Advances in cancer treatment have resulted in development and clinical use of many drugs targeting a variety of ways to eradicate tumors and to prevent the spread of tumor cells.  Yet, early diagnosis remains the most effective means for achieving favorable outcomes.  Pearsanta is focused on development of platform technologies designed for biomarker discovery and development of diagnostic tests for early detection of cancers.  The Mitomic™ platform uses mutations in mitochondrial DNA for early detection of cancer and other diseases (e.g. endometriosis) using a blood test.  The adductomics platform is designed to detect and monitor dynamic pre-mutation DNA changes (adducts) that can lead to mutations that may cause cancer.  Using these innovative tools, Pearsanta aims to improve outcomes by early detection, and possibly, prevention of cancer and other diseases.

Adivir

The recent COVID pandemic, once again, placed the spot light on infectious diseases and the potential global impact of a single infectious pathogen such as SARS-CoV-2.  Millions of people across the planet were infected and while some individuals experienced mild or no symptoms, others experienced severe morbidity and in some cases mortality.  Understanding the immune status of an individual is important prior to and after exposure to determine the level of vulnerability and for identifying individuals at greatest risk.  Immune monitoring is also useful after exposure to an infectious agent or vaccine to understand the level of immunity as well as potential harmful effects (e.g. long COVID or post-vaccination syndrome).  Adivir is focused on development of tools for better understanding of the immune status to help decision making for the individual.

Adifem

For centuries, women’s health and ailments have been viewed without a distinction in biological differences between men and women.  Many therapeutic products have been tested in clinical trials in male cohorts before commercial release.  Adifem’s interest in women’s health is based on the understanding of such differences, which lead to disease conditions that are dominant in women (e.g., most autoimmune diseases and changes such as osteoporosis following menopause, to name a few).  In concert with other collaborators in the Aditxt ecosystem, Adifem aims to develop products to improve women’s health.